AI Stock Analysis - Medpace (MEDP)
Analysis generated April 7, 2026.
Medpace Holdings, Inc. is a clinical contract research organization (CRO) offering Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries. Medpace's services include clinical trial management, medical writing, patient recruitment and retention, bioanalytical services, third-party lab management, and regulatory services. With a comprehensive suite of offerings, Medpace is well-positioned to cater to the diverse needs of the healthcare sector, helping companies expedite their drug development and approval processes.
Stock Alerts - Medpace (MEDP)
 |
Medpace | March 20 Insider Alert: GEIGER JESSE J is selling shares |
|
Medpace | March 16 Business Outlook among employees is up by 5.3% over the last month. |
|
Medpace | March 13 David Taylor (member of U.S. congress) is buying shares |
|
Medpace | March 12 Price is down by -6% in the last 24h. |
Download our app on iOS or Android to get future alerts delivered in real-time.
Alternative Data for Medpace
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 729 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 237,000 | Sign up | Sign up | Sign up |
| Employee Rating | 56 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| App Downloads | 33 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 3 | Sign up | Sign up | Sign up |
| Facebook Followers | 5,464 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,577 | Sign up | Sign up | Sign up |
| X Mentions | 7 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 883 | Sign up | Sign up | Sign up |
| News Mentions | 2 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 40 | Sign up | Sign up | Sign up |
| Linkedin Employees | 6,336 | Sign up | Sign up | Sign up |
About Medpace
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
| Price | $527.38 |
| Target Price | Sign up |
| Volume | 629,940 |
| Market Cap | $15.1B |
| Year Range | $416.04 - $620.59 |
| Dividend Yield | 0% |
| PE Ratio | 34.61 |
| Analyst Rating | 33% buy |
| Earnings Date | April 22 '26 |
| Industry | Medical Devices |
In the news
DEADLINE ALERT for PINS, NUAI, GOSS, MEDP: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsApril 20 - GlobeNewswire |
|
Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor HarmApril 17 - GlobeNewswire |
|
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit with the Schall Law FirmApril 17 - GlobeNewswire |
|
MEDP INVESTOR ALERT: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP AnnouncesApril 17 - GlobeNewswire |
|
MEDP Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Medpace Holdings, Inc. Securities Lawsuit — The Gross Law FirmApril 17 - GlobeNewswire |
|
MEDPACE LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Medpace Holdings, Inc. and Encourages Investors to Contact the FirmApril 16 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 660M | 463M | 197M | 111M | 150M | 3.860 |
| Q2 '25 | 603M | 423M | 180M | 90M | 118M | 3.103 |
| Q1 '25 | 559M | 380M | 178M | 115M | 120M | 3.670 |
| Q4 '24 | 537M | 358M | 178M | 117M | 133M | 3.681 |
| Q3 '24 | 533M | 364M | 169M | 96M | 120M | 3.010 |
Insider Transactions View All
| GEIGER JESSE J filed to sell 15,000 shares at $455.3. March 19 '26 |
| Troendle August J. filed to sell 646,184 shares at $590.7. December 4 '25 |
| Troendle August J. filed to sell 646,852 shares at $590.5. December 3 '25 |
| Troendle August J. filed to sell 652,550 shares at $593.3. December 3 '25 |
| Troendle August J. filed to sell 675,728 shares at $593.5. December 1 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| David Taylor |
Mar 9, 26 | Buy | $1K - $15K |
| Gilbert Cisneros |
Feb 16, 26 | Sell | $15K - $50K |
| David Taylor |
Feb 3, 26 | Buy | $1K - $15K |
Read more about Medpace (MEDP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, app downloads, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Medpace
The Market Cap of Medpace is $15.1B.
As of today, Medpace's PE (Price to Earnings) ratio is 34.61.
Medpace will report its next earnings on April 22 '26.
Currently, the price of one share of Medpace stock is $527.38.
The MEDP stock price chart above provides a comprehensive visual representation of Medpace's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Medpace shares. Our platform offers an up-to-date MEDP stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Medpace (MEDP) does not offer dividends to its shareholders. Investors interested in Medpace should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Medpace are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
